PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy of weekly PG2 regimen as a
complementary treatment for patients with recurrent unresectable (local or regional) or
metastatic breast cancer who experienced moderate to severe fatigue while receiving
chemotherapies.